natgillin/translations-raw huggingface dataset:
Brug af anden medicin sammen med Bortezomib Hospira Fortæl altid lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig. 
Other medicines and Bortezomib Hospira Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
• Herpes virus-infektioner 
• Herpes virus infections
Hazard ratio-estimatet er baseret på en Cox-model stratificeret efter IPI-risiko og sygdomsstadie. 
Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease.
Hætteglasset med 1 mg, 2,5 mg, 3 mg og 3,5 mg kan administreres subkutant som beskrevet nedenfor: 
The 1 mg, 2.5 mg, 3 mg and 3.5 mg vial can be administered subcutaneously, as described below.
#, forskellige grader af synsnedsættelse (inkl. 
#, Different degrees of visual impairment (up to blindness)*
Patienterne skal monitoreres nøje, når Bortezomib Hospira gives sammen med kraftige CYP3A4hæmmere. 
Patients should be closely monitored when given Bortezomib Hospira in combination with potent CYP3A4-inhibitors.
Uge B (1,3 mg/m 
Week B (1.3 mg/m
Samlet overlevelse efter 1 år (%) (95% CI) 
1-year Overall Survival (%) (95% CI)
• symptomer på tumorlysesyndrom, såsom muskelkramper, muskelsvaghed, forvirring, synstab eller synsforstyrrelser og stakåndethed 
• symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion, visual loss or disturbances and shortness of breath
Kombinationsbehandling med melphalan og prednison Bortezomib Hospira indgives som intravenøs eller subkutan injektion kombineret med oral melphalan og oral prednison som vist i tabel 2. 
Combination therapy with melphalan and prednisone Bortezomib Hospira is administered via intravenous or subcutaneous injection in combination with oral melphalan and oral prednisone as shown in Table 2.
Dag 8 Pause 
Day 8 rest period
Behandlingen med Bortezomib Hospira skal afbrydes, når thrombocyttallet er < 25.000/μl eller, ved kombinationsbehandling med melphalan og prednison, når thrombocyttallet er ≤ 30.000/μl (se pkt.4.2). 
Bortezomib Hospira therapy should be withheld when the platelet count is < 25,000/μl or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/μl (see section 4.2).
Følgende lægemidler administreres som intravenøse infusioner på dag 1 i hver 3-ugers behandlingscyklus med Bortezomib Hospira: rituximab 375 mg/m 2, cyclophosphamid 750 mg/m 2 og doxorubicin 50 mg/m 
The following medicinal products are administered on day 1 of each Bortezomib Hospira 3 week treatment cycle as intravenous infusions: rituximab at 375 mg/m 2, cyclophosphamide at 750 mg/m 2 and doxorubicin at 50 mg/m
celler/μl 
≥ 1,500 cells/μL
Sammenlignet med patienter med normal leverfunktion ændrede en let nedsættelse af leverfunktionen ikke dosis-normaliseret AUC for bortezomib. 
When compared to patients with normal hepatic function, mild hepatic impairment did not alter dose-normalised bortezomib AUC.
Patienterne i henholdsvis BTDx- og TDx-gruppen havde en medianalder på 57 vs. 56 år, 99% vs. 98 af patienterne var af kaukasisk oprindelse, og 58% vs. 54% var mænd. 
Patients in the BTDx and TDx groups respectively had a median age of 57 versus 56 years, 99% versus 98% patients were Caucasians, and 58% versus 54% were males.
Forholdet mellem fordele og risici skal overvejes, før behandlingen med Bortezomib Hospira fortsætter. 
The benefit/risk ratio should be considered prior to continuing Bortezomib Hospira therapy.
• Hurtigere hjerteslag, højt blodtryk, svedeture 
• Increased heartbeat, high blood pressure, sweating,
Mantel-Haenszel-estimat af den fælles odds ratio for stratificerede tabeller er benyttet med IPI-risiko og sygdomsstadie som stratifikationsfaktorer. 
Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors.
Bortezomib Hospira skal rekonstitueres af sundhedspersonale (se pkt. 
Bortezomib Hospira must be reconstituted by a healthcare professional (see section 6.6).
Sjælden Anafylaktisk shock, amyloidose, immunkompleks-medieret (type III) reaktion 
Anaphylactic shock, Amyloidosis, Type III immune complex mediated reaction
(95% CI)=1,688 
OR e (95% CI)=1.688
• sammen med lægemidlerne dexamethason eller dexamethason sammen med thalidomid til patienter, hvis sygdom ikke tidligere er blevet behandlet, og før de får højdosis-kemoterapi med transplantation af blodstamceller (induktionsbehandling) 
• in combination with the medicines dexamethasone or dexamethasone together with thalidomide, for patients whose disease has not been previously treated and before receiving high-dose chemotherapy with blood stem cell transplantation (induction treatment).
Tabel 2: Anbefalet dosering af Bortezomib Hospira i kombination med melphalan og prednison Bortezomib Hospira 2 gange om ugen (cyklus 1-4) 
Table 2: Recommended posology for Bortezomib Hospira in combination with melphalan and prednisone Twice weekly Bortezomib Hospira (cycles 1-4)
Rituximab 375 mg/m2, cyclophosphamid 750 mg/m2 og doxorubicin 50 mg/m2. 
Rituximab at 375 mg/m2 , cyclophosphamide at 750 mg/m2 and doxorubicin at 50 mg/m2.
• Hævelser på kroppen, blandt andet omkring øjnene og andre steder på kroppen 
• Swelling of body, to include around eyes and other parts of the body
* Primært endepunkt 
* Primary endpoint
Forekomsten af herpes zoster blandt patienter i BR-CAP-gruppen var 10,7% hos patienter, der ikke havde fået antiviral profylakse, sammenlignet med 3,6% hos patienter, der havde fået antiviral profylakse (se pkt. 
The incidence of herpes zoster among patients in the BR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 4.4).
Bortezomib Hospira skal seponeres, hvis PML diagnosticeres. 
Discontinue Bortezomib Hospira if PML is diagnosed.
Urinvejsinfektion* 
Urinary tract infection*
Patienterne i begge behandlingsgrupper fik et medianantal cyklusser på 6, hvor 14% af patienterne i BR-CAP-gruppen og 17% af patienterne i R-CHOP-gruppen fik 2 supplerende cyklusser. 
A median of 6 cycles was received by patients in both treatment arms with 14% of subjects in the BR-CAP group and 17% of patients in the R-CHOP group receiving 2 additional cycles.
Den sædvanlige startdosis af bortezomib er 1,3 mg/m2 legemsoverfladeareal to gange om ugen. 
The usual starting dose of bortezomib is 1.3 mg/m2 body surface area twice a week.
Overfølsomhed* Ikke almindelig Anafylaktisk reaktion 
Hypersensitivity* Uncommon Anaphylactic reaction
Behandling med Bortezomib Hospira skal afbrydes ved forekomst af ≥ grad 3 bortezomib-relaterede ikke-hæmatologiske toksiciteter (undtagen neuropati) eller ≥ grad 3 hæmatologiske toksiciteter (se også pkt. 
Bortezomib Hospira treatment must be withheld at the onset of any ≥ Grade 3 bortezomib-related non-haematological toxicities (excluding neuropathy) or ≥ Grade 3 haematological toxicities (see also section 4.4).
Median-TTP var 6,5 måneder for patienter i monoterapi med bortezomib sammenlignet med 9,3 måneder for patienter i kombinationsbehandling med bortezomib plus pegyleret liposomal doxorubicin. 
The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients.
BR-CAP= bortezomib, rituximab, cyclophosphamid, doxorubicin og prednison; R-CHOP= rituximab, cyclophosphamid, doxorubicin, vincristin og prednison; PN=perifer neuropati 
BR-CAP= bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
Patienterne skal derfor monitoreres omhyggeligt, når bortezomib gives sammen med kraftige CYP3A4-hæmmere (f.eks. ketoconazol, ritonavir). 
Therefore, patients should be closely monitored when given bortezomib in combination with potent CYP3A4 inhibitors (e.g. ketoconazole, ritonavir).
Alder Bortezomibs farmakokinetik er beskrevet efter intravenøs bolus-administration af 1,3 mg/m2 2 gange om ugen til 104 pædiatriske patienter (2-16 år) med akut lymfoblast leukæmi (ALL) eller akut myeloid leukæmi (AML). 
The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 paediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Du vil derfor regelmæssigt få taget blodprøver før og under din behandling med bortezomib for at kontrollere dine blodtal. 
Therefore, you will have to take regular blood tests before and during your treatment with bortezomib, to check your blood cell counts regularly.
Gastrointestinal og intracerebral blødning er blevet indberettet i forbindelse med behandling med bortezomib. 
Gastrointestinal and intracerebral haemorrhage, have been reported in association with bortezomib treatment.
Skift behandlingsplan for Bortezomib Hospira til 1,3 mg/m én gang om ugen 
Change Bortezomib Hospira treatment schedule to 1.3 mg/m2 once per week
Bortezomib Hospira kan være forbundet med træthed (meget almindeligt), svimmelhed (almindeligt), synkope (ikke almindeligt) og ortostatisk/postural hypotension eller sløret syn (almindeligt). 
Bortezomib Hospira may be associated with fatigue very commonly, dizziness commonly, syncope uncommonly and orthostatic/postural hypotension or blurred vision commonly.
Bortezomib Hospira må ikke indgives via andre administrationsveje. 
Bortezomib Hospira should not be given by other routes.
En normal leverfunktion skal bekræftes, og der skal udvises forsigtighed hos patienter, der behandles med orale antidiabetika (se pkt. 
Normal liver function should be confirmed and caution should be exercised in patients receiving oral hypoglycaemics (see section 4.5).
Der er i sjældne tilfælde indberettet potentielt immunkompleksmedierede reaktioner, for eksempel serumsyge, polyarthritis med udslæt og proliferativ glomerulonefritis. 
Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly.
Doseringsændring 
Posology modification
• Bevidsthedstab 
• Loss of consciousness
Tabel 16: Effektresultater fra forsøg LYM-3002 Effektendepunkt 
Table 16: Efficacy results from study LYM-3002 Efficacy endpoint
Der er indberettet enkelte tilfælde af krampeanfald hos patienter, som ikke tidligere har haft sådanne anfald eller epilepsi. 
Seizures have been uncommonly reported in patients without previous history of seizures or epilepsy.
• Information om, at Bortezomib Hospira 1 mg, 2,5 mg, 3 mg og 3,5 mg kan administreres både intravenøst og subkutant 
• Bortezomib Hospira 1 mg, 2.5 mg, 3 mg and 3.5 mg can be administered both intravenously and subcutaneously
• Forandringer i bevidsthedsniveau, forvirring, nedsat hukommelse eller hukommelsestab 
• Altered levels of consciousness, confusion, memory impairment or loss
Diagrammet over regimer med induktionstransplantation skal indeholde følgende nøgleelementer: 
Induction Transplant Regimens Graph shall contain the following key elements:
Nedsæt Bortezomib Hospira til 1,0 mg/m eller 
Reduce Bortezomib Hospira to 1.0 mg/m or
• Øreproblemer, blødning fra ørerne 
• Problems with your ear, bleeding from your ear
I alt har 74 evaluerbare patienter fået dexamethason sammen med bortezomib. 
A total of 74 evaluable patients were administered dexamethasone in combination with bortezomib.
Tabel 3: Dosisjusteringer under efterfølgende cyklusser med Bortezomib Hospira i kombination med melphalan og prednison 
Table 3: Posology modifications during subsequent cycles of Bortezomib Hospira therapy in combination with melphalan and prednisone
Et fase II-forsøg med en enkelt behandlingsgruppe og undersøgelse af aktivitet, sikkerhed og farmakokinetik, udført af Children's Oncology Group, vurderede man virkningen af at tilføje bortezomib til reinduktionskemoterapi med flere stoffer hos pædiatriske og unge voksne patienter med lymfoide maligniteter (akut præ-B-celle lymfoblast leukæmi [ALL], T-celle-ALL og T-celle lymfoblast lymfom [LL]). 
A Phase II, single-arm activity, safety, and pharmacokinetic trial conducted by the Children's Oncology Group assessed the activity of the addition of bortezomib to multi agent re induction chemotherapy in paediatric and young adult patients with lymphoid malignancies (pre-B cell acute lymphoblastic leukemia [ALL], T-cell ALL, and T-cell lymphoblastic lymphoma [LL]).
Hvis du får Bortezomib Hospira sammen med thalidomid, skal du følge det svangerskabsforebyggende program for thalidomid (se indlægssedlen for thalidomid). 
When bortezomib is given in combination with thalidomide you must follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide).
Tabel 10: Forekomsten af perifer neuropati i forsøg LYM-3002, inddelt efter toksicitet og behandlingsseponering på grund af perifer neuropati 
Table 10: Incidence of peripheral neuropathy in study LYM-3002 by toxicity and treatment discontinuation due to peripheral neuropathy
Antiviral profylakse bør overvejes til patienter, der behandles med Bortezomib Hospira. 
Antiviral prophylaxis is recommended in patients being treated with Bortezomib Hospira.
I fase III-forsøget til sammenligning af bortezomib administreret intravenøst vs. subkutant var forekomsten af bivirkninger med perifer neuropati ≥ grad 2 24% i gruppen, der fik subkutane injektioner, og 41% i gruppen, der fik intravenøse injektioner (p=0,0124). 
In the Phase III study comparing bortezomib administered intravenously versus subcutaneously, the incidence of Grade ≥ 2 peripheral neuropathy events was 24% for the subcutaneous injection group and 41% for the intravenous injection group (p=0.0124).
Hvis du har fået for meget Bortezomib Hospira Da dette lægemiddel gives af en læge eller sygeplejerske, er det usandsynligt, at du vil få for meget. 
As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much.
Pause Dag 
Day rest period
Der har været fatale tilfælde af utilsigtet intratekal administration af Bortezomib Hospira. 
There have been fatal cases of inadvertent intrathecal administration of Bortezomib Hospira.
Thrombocyttransfusion skal overvejes, når det er klinisk relevant (se pkt. 
Platelet transfusion should be considered when clinically appropriate (see section 4.2).
Plakaten om rekonstitution skal indeholde følgende hovedpunkter: 
The Reconstitution poster shall contain the following key elements:
Både BR-CAP og R-CHOP er mindre veltolereret hos patienter ≥ 75 år, og hyppigheden af alvorlige bivirkninger er i BR-CAP-gruppen 68% sammenlignet med 42% i R-CHOP-gruppen. 
Although in patients aged ≥ 75 years, both BR-CAP and R-CHOP were less tolerated, the serious adverse event rate in the BR-CAP groups was 68%, compared to 42% in the R-CHOP group.
• Diagram over regimer med induktionstransplantation. 
• Induction Transplant Regimens Graph.
Patienter, der får Bortezomib Hospira i kombination med thalidomid, skal overholde det særlige svangerskabsforebyggende program for thalidomid. 
Patients receiving Bortezomib Hospira in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide.
Ikke-hæmatologiske toksiciteter grad ≥ 3 
Grade ≥ 3 non-haematological toxicities
Den geometriske gennemsnitsratio AUClast var 0,99, og 90% konfidensintervaller var 80,18%-122,80%. 
The AUClast- geometric mean ratio was 0.99 and 90% confidence intervals were
Hos patienter med fremskredent myelom var sværhedsgraden af thrombocytopeni forbundet med thrombocyttallet inden behandlingen: Med et thrombocyttal ved baseline på < 75.000/μl havde 90% af 21 patienter et tal på ≤ 25.000/μl under forsøget, herunder 14% på < 10.000/μl. 
In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts < 75,000/μl, 90% of 21 patients had a count ≤ 25,000/μl during the study, including 14% < 10,000/μl; in contrast, with a baseline platelet count > 75,000/μl, only 14% of 309 patients had a count ≤ 25,000/μl during the study.
Patienter, som har bortezomib-relaterede neuropatiske smerter og/eller perifer neuropati, skal behandles som vist i tabel 1 (se pkt. 
Patients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table 1 (see section 4.4).
Det gennemsnitlige distributionsvolumen (Vd) for bortezomib er 1.659-3.294 l efter administration af intravenøse enkeltdoser eller gentagne doser på 1,0 mg/m2 eller 1,3 mg/m2 til patienter med myelomatose. 
The mean distribution volume (Vd) of bortezomib ranged from 1,659 l to 3,294 l following single- or repeated-dose intravenous administration of 1.0 mg/m2 or 1.3 mg/m2 to patients with multiple myeloma.
Tabel 6: Anbefalet justering af initialdosis af Bortezomib Hospira hos patienter med nedsat leverfunktion Grad af leversvækkelse* 
Table 6: Recommended starting dose modification for Bortezomib Hospira in patients with hepatic impairment Grade of hepatic impairment*
En periode på 6 uger anses for at være en behandlingscyklus. 
A 6-week period is considered a treatment cycle.
Læs indlægssedlerne for alle de lægemidler, du skal tage sammen med Bortezomib Hospira, for at få oplysninger om disse lægemidler, før du begynder på behandlingen med Bortezomib Hospira. 
You must read the package leaflets of all medicinal products to be taken in combination with Bortezomib Hospira for information related to these medicines before starting treatment with Bortezomib Hospira.
Bortezomib-kombinationsbehandling med dexamethason I mangel af en direkte sammenligning af bortezomib og bortezomib i kombination med dexamethason hos patienter med progressiv myelomatose blev der gennemført en statistisk "matchede par"-analyse for at sammenligne resultaterne fra den ikke-randomiserede gruppe med bortezomib i kombination med dexamethason (åbent fase II-forsøg, MMY-2045) med resultaterne fra grupperne i monoterapi med bortezomib fra forskellige randomiserede fase III-forsøg (M34101-039 [APEX] og DOXIL MMY-3001) med samme indikation. 
Bortezomib combination treatment with dexamethasone In the absence of any direct comparison between bortezomib and bortezomib in combination with dexamethasone in patients with progressive multiple myeloma, a statistical matched-pair analysis was conducted to compare results from the non randomised arm of bortezomib in combination with dexamethasone (Phase II open-label study MMY-2045), with results obtained in the bortezomib monotherapy arms from different Phase III randomised studies (M34101-039 [APEX] and DOXIL MMY-3001) in the same indication.
• Ringen for ørerne, ubehag i ørerne 
• Ringing in the ears, ear discomfort
BTDx=bortezomib, thalidomid, dexamethason; PN=perifer neuropati Bemærk: Perifer neuropati omfatter de foretrukne termer: perifer neuropati, perifer motorisk neuropati, perifer sensorisk neuropati og polyneuropati. 
BTDx=bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy Note: Peripheral neuropathy included the preferred terms: neuropathy peripheral, peripheral motor neuropathy, peripheral sensory neuropathy, and polyneuropathy.
• ketoconazol, der bruges til behandling af svampeinfektioner 
• ketoconazole, used to treat fungal infections
SGOTniveau (ASAT) 
SGOT (AST) levels
Bortezomib Hospira kan forårsage træthed, svimmelhed, besvimelse eller sløret syn. 
Bortezomib might cause tiredness, dizziness, fainting, or blurred vision.
Median-OS var 30,8 måneder (95% CI; 25,2-36,5 måneder) patienter i monoterapi med bortezomib og 33,0 måneder (95% CI; 28,937,1 måneder) for patienter i kombinationsbehandling med bortezomib plus pegyleret liposomal doxorubicin. 
The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the bortezomib monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients.
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af forsøg med referencelægemidlet, som indeholder bortezomib, i alle undergrupper af den pædiatriske population med myelomatose (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with the reference medicinal product containing bortezomib in all subsets of the paediatric population in multiple myeloma and in mantle cell lymphoma (see section 4.2 for information on paediatric use).
• Hæfte om rekonstitution, dosering og administration 
• Reconstitution, dosing and administration booklet
• Plakat om rekonstitution 
• Reconstitution poster
I dette forsøg deltog 222 patienter med recidiverende/refraktær myelomatose, der blev randomiseret i forholdet 2:1 til behandling med 1,3 mg/m2 bortezomib i 8 cyklusser, enten subkutant eller intravenøst. 
This study included 222 patients with relapsed/refractory multiple myeloma, who were randomised in a 2:1 ratio to receive 1.3 mg/m2 of bortezomib by either the subcutaneous or intravenous route for 8 cycles.
Følgende lægemidler gives som intravenøse infusioner på dag 1 i hver 21-ugers behandlingscyklus med bortezomib: 
The following medicinal products are given on day 1 of each bortezomib 21-day treatment cycle as intravenous infusions:
og s.c. anvendelse, herunder information om behovet for at skifte injektionssteder ved s.c. anvendelse 
• advice on method of administration for both IV and SC use, including the need to rotate injection sites for SC use
• Smerter i kønsorganerne, erektionsproblemer 
• Genital pain, problem having an erection
Hyperbilirubinæmi*, unormale proteinanalyser*, vægtstigning, unormal blodprøve*, forhøjet C-reaktivt protein 
Uncommon Hyperbilirubinaemia*, Protein analyses abnormal*, Weight increased, Blood test abnormal*, C-reactive protein increased
De væsentligste effektresultater ses i tabel 13. 
Main efficacy results are presented in Table 13.
Varigheden af det samlede respons var 21,4 måneder længere i BRCAP-gruppen (medianværdi 36,5 måneder vs. 15,1 måneder i R-CHOP-gruppen). 
The duration of overall response was 21.4 months longer in the BR-CAP group (median 36.5 months versus 15.1 months in the R-CHOP group).
I forsøg med patienter med recidiverende myelomatose, som blev behandlet med bortezomib, og med patienter med tidligere ubehandlet MCL, som blev behandlet med bortezomib i kombination med rituximab, cyclophosphamid, doxorubicin og prednison (BR-CAP), var en af de mest almindelige hæmatologiske bivirkninger forbigående thrombocytopeni. 
In studies in patients with relapsed multiple myeloma treated with bortezomib and in patients with previously untreated MCL treated with bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (BR-CAP), one of the most common haematologic toxicity was transient thrombocytopenia.
I en multivariansanalyse var responsraten uafhængig af myelomtype, performance status, kromosom 13-deletionsstatus og antallet eller typen af tidligere behandlinger. 
performance status, chromosome 13 deletion status, or the number or type of previous therapies.
Den estimerede 4-årige overlevelsesrate var 53,9% i R-CHOP-gruppen og 64,4% i BR-CAP-gruppen. 
There was a trend towards prolonged overall survival favouring the BR-CAP group; the estimated 4-year survival rate was 53.9% in the R-CHOP group and 64.4% in the BR-CAP group.
Sjælden Malign neoplasme, leukaemia plasmacytica, nyrecellekarcinom, masse, mycosis fungoides, benign neoplasme* 
Neoplasm malignant, Leukaemia plasmacytic, Renal cell carcinoma, Mass, Mycosis fungoides, Neoplasm benign*
Dag 1, 2, 3, 4 Dag 8, 9, 10, 11Cyklus 2 til 4 
Day 1, 2, 3, 4 Day 8, 9, 10, 11Cycles 2 to 4
Neutrofiltallet var lavest på dag 11 i hver cyklus af behandling med bortezomib og var typisk vendt tilbage til baseline-niveau ved den næste cyklus. 
Neutrophils were lowest at Day 11 of each cycle of bortezomib treatment and typically recovered to baseline by the next cycle.